Ivan Hyep Sells 13,555 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 13,555 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $18.22, for a total value of $246,972.10. Following the transaction, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,648,368.10. This represents a 8.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.25, for a total value of $54,074.75.
• On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $34,158.30.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $18.47 on Friday. The stock’s 50 day moving average price is $16.47 and its 200 day moving average price is $15.75. The firm has a market capitalization of $1.01 billion, a PE ratio of -8.25 and a beta of -0.78. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.71.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BCAX. Citigroup began coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Wells Fargo & Company boosted their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Finally, UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP raised its position in shares of Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after purchasing an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $44,484,000. Vanguard Group Inc. increased its stake in shares of Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after buying an additional 195,667 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Bicara Therapeutics by 179.5% in the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after buying an additional 1,059,260 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.